News Boehringer latest to axe Alzheimer's drug Company will trial BI 409306 in schizophrenia instead.
News Axovant CEO David Hung quits after Alzheimer's drug failure Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.
News Tysabri failure in stroke a setback for Biogen Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed.
News Novartis/Amgen migraine drug reduces attacks after others fa... Aimovig notches up another late-stage trial success
News Regeneron: Biobank project offers hope for Alzheimer's R&D Regeneron R&D chief hopes UK data could find new Alzheimer's and Parkinson's drugs
News Roche's Ocrevus MS drug approved in EU Already a big hit in the US, Ocrevus set to make debut in EU.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
